377 related articles for article (PubMed ID: 27591414)
1. Rationale for anti-GITR cancer immunotherapy.
Knee DA; Hewes B; Brogdon JL
Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
[TBL] [Abstract][Full Text] [Related]
2. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
3. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
4. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
5. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
6. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
7. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy.
Riccardi C; Ronchetti S; Nocentini G
Expert Opin Ther Targets; 2018 Sep; 22(9):783-797. PubMed ID: 30107134
[TBL] [Abstract][Full Text] [Related]
8. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
9. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
10. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
11. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
13. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
14. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
15. New emerging targets in cancer immunotherapy: the role of GITR.
Buzzatti G; Dellepiane C; Del Mastro L
ESMO Open; 2020 Aug; 4(Suppl 3):e000738. PubMed ID: 32817129
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
17. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
18. Modulation of GITR for cancer immunotherapy.
Schaer DA; Murphy JT; Wolchok JD
Curr Opin Immunol; 2012 Apr; 24(2):217-24. PubMed ID: 22245556
[TBL] [Abstract][Full Text] [Related]
19. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]